Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

The Lancet

Volumn 395, Issue 10239, 2020, Pages 1763-1770

  Cummings, Matthew J ^a   Baldwin, Matthew R ^a   Abrams, Darryl ^a   Jacobson, Samuel D ^b   Meyer, Benjamin J ^b   Balough, Elizabeth M ^b   Aaron, Justin G ^a   Claassen, Jan ^a   Rabbani, LeRoy E ^a   Hastie, Jonathan ^a   Hochman, Beth R ^a   Salazar Schicchi, John ^a   Yip, Natalie H ^a   Brodie, Daniel ^a   O'Donnell, Max R ^a,c  

^a NewYork Presbyterian Hospital   (United States)

^b Columbia University ^*  (United States)

^c Columbia University Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE FACTOR; INTERLEUKIN 6; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC DISEASE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DETERIORATION; DIABETES MELLITUS; DISEASE COURSE; DRUG USE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITAL MORTALITY; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEW YORK; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; UNIVERSITY HOSPITAL; ADULT RESPIRATORY DISTRESS SYNDROME; BETACORONAVIRUS; BLOOD; CLINICAL TRIAL; CORONAVIRUS INFECTION; CRITICAL ILLNESS; HOSPITALIZATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANDEMIC; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY; VIROLOGY; VIRUS PNEUMONIA; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BETACORONAVIRUS; BIOMARKERS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEW YORK CITY; PANDEMICS; PNEUMONIA, VIRAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; YOUNG ADULT;

EID: 85085686967     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)31189-2     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases in the U.S. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. (Accessed 28 April 2020)
2. New York State Department of Health. COVID-19 tracker. https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n. (Accessed 28 April 2020)
3. Wu, Z, McGoogan, JM, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020 published online Feb 24. DOI:10.1001/jama.2020.2648.
4. Guan, WJ, Ni, ZY, Hu, Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382 (2020), 1708–1720.
5. Grasselli, G, Pesenti, A, Cecconi, M, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA, 2020 published online March 13. DOI:10.1001/jama.2020.4031.
6. Yang, X, Yu, Y, Xu, J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020 published online Feb 24. https://dx.doi.org/10.1016/S2213-2600(20)30079-5.
7. Zhou, F, Yu, T, Du, R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 (2020), 1054–1062.
8. Grasselli, G, Zangrillo, A, Zanella, A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA, 2020 published online April 6. DOI:10.1001/jama.2020.5394.
9. Arentz, M, Yim, E, Klaff, L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA, 2020 published online March 19. DOI:10.1001/jama.2020.4326.
10. Bhatraju, PK, Ghassemieh, BJ, Nichols, M, et al. COVID-19 in critically ill patients in the Seattle region—case series. N Engl J Med, 2020 published online March 30. DOI:10.1056/NEJMoa2004500.
11. WHO. R&D Blueprint: COVID-19 therapeutic trial synopsis. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf, Feb 18, 2020. (Accessed 11 April 2020)
12. Mehta, P, McAuley, DF, Brown, M, Sanchez, E, Tattersall, RS, Manson, JJ, COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395 (2020), 1033–1034.
13. Helms, J, Tacquard, C, Severac, F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med, 2020 published online May 4. DOI:10.1007/s00134-020-06062-x.
14. Kelly, CA, Upex, A, Bateman, DN, Comparison of consciousness level assessment in the poisoned patient using the alert/verbal/painful/unresponsive scale and the Glasgow Coma Scale. Ann Emerg Med 44 (2004), 108–113.
15. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 69 (2020), 343–346.
16. Wu, C, Chen, X, Cai, Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 2020 published online March 13. DOI:10.1001/jamainternmed.2020.0994.
17. Ruan, Q, Yang, K, Wang, W, Jiang, L, Song, J, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020 published online March 3. DOI:10.1007/s00134-020-05991-x.
18. Zhou, Y, Fu, B, Zheng, X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev, 2020 published online March 13. DOI:10.1093/nsr/nwaa041.
19. Thachil, J, Tang, N, Gando, S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18 (2020), 1023–1026.
20. Zheng, YY, Ma, YT, Zhang, JY, Xie, X, COVID-19 and the cardiovascular system. Nat Rev Cardiol 17 (2020), 259–260.
21. Naicker, S, Yang, CW, Hwang, SJ, Liu, BC, Chen, JH, Jha, V, The novel coronavirus 2019 epidemic and kidneys. Kidney Int 97 (2020), 824–828.
22. Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports. (Accessed 11 April 2020)
23. New York State Department of Health. New York State Community Health Indicator Reports (CHIRS). https://www.health.ny.gov/statistics/chac/indicators/. (Accessed 12 May 2020)
24. Wang, M, Cao, R, Zhang, L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271.
25. Wang, Y, Zhang, D, Guanhua, D, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020 published online April 29. https://doi.org/10.1016/S0140-6736(20)31022-9.
26. US Food and Drug Administration. Remdesivir Emergency Use Authorization. https://www.fda.gov/media/137564/download, May 1, 2020. (Accessed 12 May 2020)
27. Geleris, J, Sun, Y, Platt, J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med, 2020 published online May 7. DOI:10.1056/NEJMoa2012410.
28. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. MMWR Morb Mortal Wkly Rep 69 (2020), 477–481.
29. Bhala, N, Curry, G, Martineau, AR, Agyemang, C, Bhopal, R, Sharpening the global focus on ethnicity and race in the time of COVID-19. Lancet, 2020 published online May 8. https://doi.org/10.1016/S0140-6736(20)31102-8.